BrainsWay (NASDAQ:BWAY – Get Rating) had its target price decreased by Raymond James from $8.00 to $3.75 in a report released on Monday morning, Benzinga reports. Raymond James currently has an outperform rating on the stock.
A number of other analysts have also issued reports on the company. Northland Securities lowered their price target on BrainsWay from $15.00 to $5.00 and set an outperform rating on the stock in a research note on Thursday, November 17th. HC Wainwright boosted their price objective on BrainsWay from $15.00 to $16.00 and gave the stock a buy rating in a research note on Monday, August 22nd.
BrainsWay Trading Up 2.1 %
Shares of BWAY stock opened at $1.99 on Monday. The stock has a 50 day moving average of $3.34 and a 200 day moving average of $4.72. The stock has a market cap of $32.87 million, a P/E ratio of -6.22 and a beta of 1.42. BrainsWay has a twelve month low of $1.90 and a twelve month high of $9.18.
Institutional Investors Weigh In On BrainsWay
BrainsWay Company Profile
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
- Get a free copy of the StockNews.com research report on BrainsWay (BWAY)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.